Hope is on the way for one of the world’s most common sexual problems

9 August 2017

Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age. 

Go to article (external link)

About Starpharma

This document contains Forward Looking Statements

For Further Information

© Starpharma Holdings Limited 2017